• 27602 Citations
19982020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Novel biomarkers of endocrine resistance in breast cancer. Circulating tumor cells (CTCs) and ctDNA. Drug development with focus on endocrine therapy.

Management of breast cancer with particular focus on inflammatory breast cancer (IBC), Locally Advanced Breast Cancer (LABC) and Metastatic Breast Cancer (MBC). Expertise in new endocrine therapies for hormone-receptor positive MBC.

Training Experience

1994Internship, Cabrini Medical Center, New York, NY
1996Residency, Cabrini Medical Center, New York, NY
1998Fellowship, University of Texas/MD Anderson Cancer Center

Education/Academic qualification

MD, University of Rome La Sapienza

… → 1986

Research interests

  • Breast Cancer
  • Cancer Genetics
  • Chemotherapy
  • Molecular Diagnostics
  • Oncology

Fingerprint Dive into the research topics where Massimo Cristofanilli is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Research Output

Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)

Rolfo, C., Cardona, A. F., Cristofanilli, M., Paz-Ares, L., Diaz Mochon, J. J., Duran, I., Raez, L. E., Russo, A., Lorente, J. A., Malapelle, U., Gil-Bazo, I., Jantus-Lewintre, E., Pauwels, P., Mok, T. & Serrano, M. J., Jul 2020, In : Critical Reviews in Oncology/Hematology. 151, 102978.

Research output: Contribution to journalReview article

  • Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033))

    Cristofanilli, M., Harbeck, N., Rugo, H. S., Castrellon, A., Joy, A. A., Verma, S., Im, S. A., Iyer, S., Puyana Theall, K., Gauthier, E., Huang, X., Bartlett, C. H., Loibl, S. & Finn, R. S., Feb 2020, In : Breast. 49, 1 p.

    Research output: Contribution to journalComment/debate

    Open Access
  • Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

    Gelmon, K. A., Cristofanilli, M., Rugo, H. S., DeMichele, A. M., Joy, A. A., Castrellon, A., Sleckman, B., Mori, A., Theall, K. P., Lu, D. R., Huang, X., Bananis, E., Finn, R. S. & Slamon, D. J., Mar 1 2020, In : Breast Journal. 26, 3, p. 368-375 8 p.

    Research output: Contribution to journalArticle

    Open Access
  • 2 Scopus citations

    Genetic variants detected using cell-free DNA from blood and tumor samples in patients with inflammatory breast cancer

    Winn, J. S., Hasse, Z., Slifker, M., Pei, J., Arisi-Fernandez, S. M., Talarchek, J. N., Obeid, E., Baldwin, D. A., Gong, Y., Ross, E., Cristofanilli, M., Alpaugh, R. K. & Fernandez, S. V., Feb 2 2020, In : International journal of molecular sciences. 21, 4, 1290.

    Research output: Contribution to journalArticle

    Open Access
  • Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Pooled analysis from randomized phase 2 and 3 studies

    Ettl, J., Im, S. A., Ro, J., Masuda, N., Colleoni, M., Schnell, P., Bananis, E., Lu, D. R., Cristofanilli, M., Rugo, H. S. & Finn, R. S., Mar 12 2020, In : Breast Cancer Research. 22, 1, 27.

    Research output: Contribution to journalArticle

    Open Access